ArticleJournal of hepatology2026
Tissue-specific regulation of PNPLA3 promotes lipid remodeling in response to dietary and environmental challenges.
Article in Journal of hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hepatic LGALS4 Alleviates Diet-Induced Steatosis by Promoting AMPK-Dependent Fatty Acid Oxidation.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
- Update of
Authors and funding
4 authors.
Funding
Abstract
BACKGROUND &
aimsPNPLA3(I148M) is the strongest genetic risk factor for steatotic liver disease (SLD), but its functional role and tissue-specific regulation remain unclear. Pnpla3 mRNA levels are significantly higher in mouse adipose tissue than in liver tissue, yet its role in adipose tissue is not known. Here, we characterize the molecular mechanisms underlying tissue-specific differences in PNPLA3 expression in mice to clarify its functional role and link to SLD risk.
methodsPnpla3 mRNA and PNPLA3 protein levels were quantified in liver tissue and adipose depots of fasted and refed mice at 30 °C and 6 °C. Signaling pathways regulating PNPLA3 expression in adipocytes were examined using adrenergic agonists and pathway-specific modulators. Translation and proteasomal inhibitors were used during adrenergic stimulation to investigate the discordance between Pnpla3 mRNA and protein levels. The relationship between PNPLA3 levels and triglyceride (TG) fatty acid composition was also assessed.
resultsAt thermoneutrality, feeding strongly increased PNPLA3 levels in the liver, but it remained undetectable in adipose tissue. Conversely, cold exposure or β3-adrenergic stimulation had no effect on hepatic PNPLA3 but increased PNPLA3 >19-fold in brown adipose tissue (BAT), despite causing a >75% reduction in Pnpla3 mRNA, indicating robust post-translational regulation. In BAT, adrenergic signaling via cAMP/PKA and PI3K/AKT elevated PNPLA3 by reducing proteasomal degradation. PNPLA3 expression correlated with depletion of TG-long-chain polyunsaturated fatty acids (TG-LCPUFAs) in both the liver and BAT, consistent with a role in lipid remodeling.
conclusionsThese findings reveal striking tissue- and context-specific regulation of PNPLA3, but a conserved association between its expression and TG-LCPUFAs levels, suggesting that PNPLA3 modulates lipid remodeling in response to metabolic stress and that disrupting this function may contribute to SLD susceptibility. IMPACT AND IMPLICATIONS: Despite being the strongest genetic risk factor for steatotic liver disease, PNPLA3's physiological role remains unclear. Using mouse models, this study reveals that PNPLA3 is regulated in a tissue-specific manner in response to feeding and cold exposure, thereby promoting remodeling of cellular lipids to adapt to dietary and environmental challenges. The localization of PNPLA3 action and its tissue-specific regulation are directly relevant to hepatologists and metabolic researchers aiming to understand its influence on intracellular lipid composition and its effects on disease susceptibility. Moreover, modulation of PNPLA3 turnover - and its impact on long-chain polyunsaturated fatty acid remodeling - emerges as a potential therapeutic strategy for regulating lipid homeostasis in steatotic liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.